Drug Profile
ITD 1
Alternative Names: ITD-1Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator ChemRegen; Human BioMolecular Research Institute; Sanford Burnham Prebys Medical Discovery Institute
- Class Heart failure therapies; Stem cell therapies
- Mechanism of Action Transforming growth factor beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Heart failure
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Heart-failure in USA (Parenteral, Injection)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Heart-failure in USA (PO, Pill)
- 01 Aug 2016 ITD 1 is available for licensing as of 01 Aug 2016. http://chemregen.com/